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‘Erythema Multiforme associated with Phenytoin And Cranial radiation Therapy’ (EMPACT) is a very rare
clinic situation and classiﬁed in EM-like drug reactions. It can be easily misdiagnosed as acute urticaria or
drug eruption in ED. Initial symptoms may resemble a simple skin problem, but diagnosing and early
hospitalization of the patients can be lifesaving. Here, we present a man with renal cell cancer and brain
metastases who admitted to ED due to fever and generalized rash. His skin lesions beginning from his
head and spreading through the torso appeared four days after the end of radiotherapy (11 days after the
initial dose of both radiation and oral phenytoin). Inspection showed erythematous lesions on the scalp,
neck, torso and arms. These lesions had desquomative character on the scalp. Erythematous mac-
ulopapular lesions with the tendency of fusion were also visible on the chest, abdomen, back, on the
ﬂexor areas of the arm, forearm and femoral region. Laboratory studies showed normal complete blood
counts, high creatinine kinase, creatinine kinase-MB, gamma-glutamyl transpeptidase, aspartate
aminotransferase, lactate dehydrogenase, albumin and total protein. After discontinuation of phenytoin
and giving H1, H2 receptor blockers and steroid intravenously, he was discharged two weeks later with
full recovery.
Copyright © 2016 The Emergency Medicine Association of Turkey. Production and hosting by Elsevier
B.V. on behalf of the Owner. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
‘Erythema Multiforme associated with Phenytoin And Cranial
radiation Therapy’ (EMPACT), ﬁrst introduced by Ahmed et al in
2004,1 is erythema multiforme (EM) in patients who takes cranial
radiotherapy accompanying with phenytoin medication. The
reason is thought as the increase in adverse effect of the anticon-
vulsant due to radiotherapy.2
In this syndrome, the patients can be presented in a wide range
of clinical spectrum from a simple erythema multiforme to com-
plex toxic epidermal necrolysis (TEN).3 Mortality is closely associ-
ated with the therapy given and the severity of TEN. Leading causes
of mortality are sepsis and multiorgan failure.2,3 Other important
complications are pulmonary embolism, renal failure, ﬂuid-
electrolyte imbalance, thrombocytopenia and leukopenia.3Fakultesi Hastanesi, Acil Tip
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ons.org/licenses/by-nc-nd/4.0/).Here, we present a man with renal cell cancer and brain me-
tastases who admitted to the emergency department (ED) due to
fever and generalized rash. Emergency physicians should be aware
of this syndrome before giving the decision of discharge.2. Case presentation
A 41-year-old man admitted to our ED due to malaise, fever,
sores in the mouth and generalized rash. His anamnesis revealed
that the diagnosis of renal cell cancer was put three years ago and
then he had a nephrectomy operation from the right. Because of
brain metastases, he had been given full brain radiotherapy 20 days
ago. Concurrent phenytoin sodium (Epanutin©, Pﬁzer, Turkey) was
given to the patient 300 mg daily for seizure prophylaxis. He had
also hypothyroidism for 10 years and on levothyroxine 0.1 mg/day.
Generalized rash beginning from his head and spreading through
the torso appeared four days after the end of radiotherapy (11 days
after the initial dose of both radiation and oral phenytoin). He had
treated in dermatology unit of a state hospital with the diagnoses of
drug eruption and/or acute urticaria.
During his hospitalization, he had also taken imipenem 500 mg/
days intravenously for three days due to prediagnosis of hospitaln and hosting by Elsevier B.V. on behalf of the Owner. This is an open access article
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viated, he was discharged voluntarily and had admitted our ED.
His initial vital signs were within normal limits. Inspection
showed erythematous lesions on the scalp, neck, torso and arms
(Fig 1). These lesions had desqumative character on the scalp.
Erythematous maculopapular lesions with the tendency of fusion
were also visible on the chest, abdomen, back, on the ﬂexor areas of
the arm, forearm and femoral region. Oral mucosa was dehydrated
and aphthous lesions were remarkable in the oropharynx with
crust on the lips. His other physical examination signs were
unremarkable.
Laboratory studies showed normal complete blood counts, high
creatinine kinase (138 U/L, range: 1e24), creatinine kinase-MB
(127 U/L, range: 1e171), gamma-glutamyl transpeptidase (107 U/
L, range: 1e55), aspartate aminotransferase (52 U/L, range: 1e50),
lactate dehydrogenase (692 U/L, range: 1e247), albumin (2,9 g/dl,
range: 3,5-5,2) and total protein (5,5 g/dl, range: 6,6e8,8). Hep-
atobiliary ultrasound showed paraaortic and paracaval lymphade-
nopathies. We stopped phenytoin, gave H1 and H2 receptor
blockers as well as steroid intravenously in ED and hospitalized him
in dermatology clinic with the diagnosis of EMPACT. There, he was
given daily levetiracetam 500 mg for seizure prophylaxis, H1 and
H2 receptor blockers and prednisolone 80 mg additional to ﬂuid
and supportive treatment. He was discharged twoweeks later with
full recovery of the skin lesions.
3. Discussion
EMPACT syndrome is a very rare clinic situation and classiﬁed in
EM-like drug reactions. About thirty cases have been described so
far.1,2,4 No correlation was found between size and severity of
cutaneous eruptions and the dose of phenytoin or radiation ther-
apy, or the origin or size of intracranial malignancy.3,5 In previous
case reports, associated cancers were glioblastoma multiforme,
glioma, astrocytoma or tumors with brain metastases like lungFig. 1. Erythematous maculopapular desquomative lesions with the tendcancer, breast cancer, germinoma, melanoma, angiosarcoma,
chondrosarcoma or bronchial carcinoma. However, nothing yet
reported about renal cell cancer as it was in our case.2
It is known that phenytoin use may cause a wide range of
cutaneous lesions with the leading sign of examatous eruptions
(8.5%e19%). EM is far rarer.1,6 Differential diagnosis is important.
Acute radiation dermatitis due to radiotherapy is dose dependent
and limited in the radiation exposured skin area.1 Dermatological
lesions occur at the same time in phenytoin induced drug eruption,
however in EMPACT, rash begins from the area where radiotherapy
was given and spreads through the whole body the following days.
The duration of cutaneous lesions after radiotherapy is typically
between 7 and 35 (mean 23) days in EMPACT. A fast improvement
can be achieved with just stopping phenytoin.1,3 In our case, the
rash had begun from the head through the torso 11 days after the
ﬁrst radiation.
Pathophysiologic mechanism of EMPACT is not yet clear. Many
mechanisms were asserted in the pathway of phenytoin meta-
bolism. Animal studies showed that radiation to brain may cause a
rise in cellular autoimmunity by upregulating mRNA expression of
immunologic cytokines in rats.5 Radiation may also induce a defect
in epoxide hydrolase, an enzyme that breaks down the drug,
causing accumulation of oxidative metabolites.2,5 Additionally,
phenytoin and its metabolites can activate CD4, CD8 T-cells and
diminish the functions of T-suppressor, NK and B cells.7,8 These
changes in immune system may lead to form autoantibodies
causing cutaneous phenytoin reactions.2 Phenytoin induced type 4
hypersensitivity is another mechanism to be blamed.2
Discontinue of phenytoin is the main point of the initial treat-
ment. Although the efﬁcacy of the systemic therapeutic agents is
controversial, high dose steroid and intravenous immunoglobulin-
G can be used. Plasmapheresis, cyclosporine and cyclophospha-
mide are other alternative curative regimens.3 We used high dose
steroid and supportive treatment in our patient. Gabapentin and
levetiracetam are preferable for prevention of seizures instead ofency of fusion on the scalp (A), torso (B, C) and extremities (D, E, F).
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lesions as other anti-epileptic drugs like phenobarbital, valproic
acid, and carbamazepine had been associated with EM. Addition-
ally, both carbamazepine and barbiturates may cause cross-
reactions in patients that are sensitive to phenytoin as they share
same aromatic chain in their chemical structure.1,2,54. Conclusion
In conclusion, a case of EMPACT syndrome can be easily mis-
diagnosed as acute urticaria or drug eruption in ED. Phenytoin and
cranial radiotherapy concomitance is frequent but reported
EMPACT cases are rare may be because the clinicians do not give
attention to this concordance. Initial symptoms may resemble a
simple skin problem, but diagnosing and early hospitalization of
patients with this syndrome can be lifesaving.Conﬂicts of interest
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